Thomas Trimarchi - 23 Jul 2024 Form 3 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
President and COO
Signature
/s/ Brian C. Stephenson, Attorney-in-Fact
Issuer symbol
BBIO
Transactions as of
23 Jul 2024
Net transactions value
$0
Form type
3
Filing time
29 Jul 2024, 20:16:08 UTC
Next filing
08 Aug 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BBIO Common Stock 394,856 23 Jul 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BBIO Stock Option (Right to Buy) 23 Jul 2024 Common Stock 115,000 $17.00 Direct F1
holding BBIO Stock Option (Right to Buy) 23 Jul 2024 Common Stock 16,419 $42.19 Direct F2
holding BBIO Stock Option (Right to Buy) 23 Jul 2024 Common Stock 22,145 $68.87 Direct F3
holding BBIO Stock Option (Right to Buy) 23 Jul 2024 Common Stock 158,127 $40.03 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option is fully vested and exercisable. The stock option vested in 48 monthly installments from June 26, 2019 to June 26, 2023.
F2 The stock option is fully vested and exercisable. The stock option vested as to 2,736 shares on October 18, 2020 and as to the remainder of the shares in 40 monthly installments thereafter through February 18, 2024.
F3 18,915 of the shares subject to this option are vested and exercisable. The option vests in 48 equal monthly installments from February 10, 2021 to February 10, 2025, subject to the Reporting Person's continued service to the Issuer through each such date.
F4 102,123 of the shares subject to this option are vested and exercisable. The option vested as to 25% of the shares on December 2, 2022 and as to the remainder of the shares in 36 monthly installments thereafter through December 2, 2025, subject to the Reporting Person's continued service to the Issuer through each such date.

Remarks:

Exhibit 24 - Power of Attorney